DBV Technologies's earnings have been declining at an average annual rate of -4.4%, while the Biotechs industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 2.4% per year.
Key information
-4.39%
Earnings growth rate
20.05%
EPS growth rate
Biotechs Industry Growth
-14.59%
Revenue growth rate
2.40%
Return on equity
-80.54%
Net Margin
-2,919.23%
Next Earnings Update
29 Jul 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How DBV Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
XTRA:DBV Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
6
-167
45
129
31 Dec 25
6
-147
36
117
30 Sep 25
6
-125
29
103
30 Jun 25
4
-122
28
98
31 Mar 25
4
-114
29
89
31 Dec 24
4
-114
31
89
30 Sep 24
13
-102
34
83
30 Jun 24
14
-88
33
73
31 Mar 24
15
-80
33
66
31 Dec 23
16
-73
32
60
30 Sep 23
6
-101
31
77
30 Jun 23
5
-101
29
78
31 Mar 23
4
-100
26
79
31 Dec 22
5
-96
26
76
30 Sep 22
9
-71
24
58
30 Jun 22
8
-77
29
59
31 Mar 22
5
-85
32
60
31 Dec 21
6
-98
35
70
30 Sep 21
2
-124
39
85
30 Jun 21
4
-131
38
94
31 Mar 21
9
-148
37
96
31 Dec 20
11
-160
45
102
30 Sep 20
17
-161
54
100
30 Jun 20
16
-171
63
102
31 Mar 20
16
-169
74
110
31 Dec 19
15
-172
75
111
30 Sep 19
12
-176
77
112
30 Jun 19
13
-198
90
122
31 Mar 19
13
-191
87
119
31 Dec 18
13
-190
87
120
30 Sep 18
11
-178
77
117
30 Jun 18
11
-172
68
118
31 Mar 18
11
-182
69
126
31 Dec 17
12
-177
64
124
30 Sep 17
11
-169
63
119
30 Jun 17
11
-157
61
109
31 Mar 17
9
-135
54
91
31 Dec 16
8
-121
51
81
30 Sep 16
8
-109
47
72
30 Jun 16
8
-88
39
59
31 Mar 16
8
-72
31
50
31 Dec 15
7
-49
20
36
30 Sep 15
6
-40
16
31
30 Jun 15
6
-30
11
25
Quality Earnings: DBV is currently unprofitable.
Growing Profit Margin: DBV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DBV is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare DBV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DBV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.2%).
Return on Equity
High ROE: DBV has a negative Return on Equity (-80.54%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/31 15:39
End of Day Share Price
2026/05/29 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DBV Technologies S.A. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.